Prevalence of atrial fibrillation in patients taking TSH suppression therapy for management of thyroid cancer

Clinical and Investigative Medicine

Volumn 35, Issue 3, 2012, Pages

  Abonowara, Abdulgani ^a   Quraishi, Ata ^a   Sapp, John L ^a   Alqambar, Mohammed H ^a   Saric, Adi ^b   O'Connell, Colleen M ^a   Rajaraman, Murali M ^a   Hart, Robert D ^a   Imran, Syed A ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

THYROTROPIN; THYROXINE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; CROSS-SECTIONAL STUDY; DRUG ANTAGONISM; ELECTROCARDIOGRAPHY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MALE; MIDDLE AGED; PREVALENCE; THYROID TUMOR;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; CROSS-SECTIONAL STUDIES; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; THYROID NEOPLASMS; THYROTROPIN; THYROXINE; YOUNG ADULT;

EID: 84865415198     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thy roid. 2006; 16:1229-42.
2. Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statis tics Review, 1975-2008, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2008/, based on Novem ber 2010 SEER data submission, posted to the SEER web site, 2011.
3. Svare A, Nilsen TI, Bjoro T, et al. Hyperthyroid levels of TSH correlate with low bone mineral density: the HUNT 2 study. Eur J Endocrinol. 2009; 161:779-86.
4. Flynn R, Bonellie S, Jung R, et al. Serum Thyroid-Stimulating Hormone Concentration and Morbidity from Cardiovascular Disease and Fractures in Patients on Long-Term Thyroxine Ther apy; The Journal of Clinical Endocrinology & Metabolism 2010; 95 no. 1 186-193.
5. Camm A, Kirchhof P, Lip G, et al; European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010; 12:1360-1420
6. Sawin C, Geller A, Wolf P, et al. Low serum thyrotropin concen trations as a risk factor for atrial fibrillation in older persons. N EnglJMed. 1994; 10; 331:1249-52.
7. Biondi B, Cooper DS. The clinical significance of subclinical thyroid disease. Endocr Rev 2008; 29: 76-131
8. Go A, Hylek E, Phillips K, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm manage ment and stroke prevention: the Anticoagulation and Risk Fac tors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001; 9; 285:2370-5.
9. Cooper D, Doherty G, Haugen B, et al. American Thyroid As sociation (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid As sociation management guidelines for patients with thyroid nod ules and differentiated thyroid cancer. Thyroid. 2009; 19:1167-214.
10. Heeringa J, Van der Kuip D, Hofman A, et al. Prevalence, inci dence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006; 27:949-53.
11. Cea-Calvo L, RedonJ, LozanoJ, et al. Prevalence of atrial fibril lation in the Spanish population aged 60 years or more. The PREV-ICTUS study, Rev Esp Cardiol 2007, 60: 6.616-624.
12. Stewart S, Hart C, Hole D, et al. Population prevalence, inci dence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart. 2001; 86: 516-521.
13. Miyasaka Y, Barnes M, Gersh B, et al. Secular Trends in Inci dence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future Prevalence. Circulation. 2006; 114: 119-125.
14. Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005; 26:2422-2434.
15. Nabauer M, Gerth A, Limbourg T, et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace 2009; 11: 423-434.
16. Barry J, Maron, Jeffrey A, Towbin, et al. Contemporary Defini tions and Classification of the Cardiomyopathies. Circulation 2006; 113:1807-1816
17. Chugh S, Blackshear J, Shen W, et al. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol 2001; 37:371-8.
18. Frost L, Vestergaard P, Mosekilde L. Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study. Arch Intern Med 2004; 9-23; 164:1675-8.
19. Cappola AR, Fried LP, Arnold AM et al. Thyroid status, cardio vascular risk and mortality in older adults. JAMA 2006; 295: 1033-1041.
20. Biondi B, Fazio S, Carella C, et al. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J Clin En docrinol Metab 1993; 77:334-338.
21. Ching G, Franklyn J, Stallard T, et al. Cardiac hypertrophy as a result of long-term thyroxine therapy and thyrotoxicosis. Heart 1996; 75:363-368.
22. Smith S, Feldman T, Hirshfeld J, et al. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. J Am Coll Cardiol, 2006; 47:1-121.
23. Shapiro L, Sievert R, Ong L, et al. Minimal cardiac effects in asymptomatic athyreotic patients chronically treated with thyrotropin-suppressive doses of L-thyroxine. J Clin Endocrinol Metab. 1997; 82:2592-2595.
24. Pujol P, Daures JP, Nsakala N, et al. Degree of thyrotropin sup pression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab, 1996; 81: 4318-4323